SCHEMBL5737822

SCHEMBL5737822

CC(Oc1cc(OC2CCOCC2)c2c(Nc3c(Cl)ccc4c3OCO4)ncnc2c1)C1CCNCC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 19/20 0.71
KDR P35968 10/20 0.67
EGFR P00533 2/20 0.66
LCK P06239 2/20 0.66
YES1 P07947 2/20 0.66
CSK P41240 2/20 0.66
PKMYT1 Q99640 2/20 0.66
BMPR1B O00238 1/20 0.66
GAK O14976 1/20 0.66
EPHB6 O15197 1/20 0.66
RIPK2 O43353 1/20 0.66
STK10 O94804 1/20 0.66
MAP4K4 O95819 1/20 0.66
ABL1 P00519 1/20 0.66
FYN P06241 1/20 0.66
LYN P07948 1/20 0.66
RET P07949 1/20 0.66
HCK P08631 1/20 0.66
PDGFRB P09619 1/20 0.66
FGR P09769 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274750 0.91 SRC (0.82) SRCKDREGFRLCKYES1
SCHEMBL3196245 0.87 SRC (0.82) SRCKDREGFRLCKYES1
SCHEMBL3193688 0.86 SRC (0.81) SRCKDREGFRLCKYES1
SCHEMBL3280393 0.85 SRC (0.82) SRCKDREGFRLCKYES1
SCHEMBL3282949 0.84 SRC (0.69) SRCKDREGFRLCKYES1
SCHEMBL3283111 0.84 SRC (0.88) SRCKDREGFRLCKYES1
SCHEMBL5951031 0.83 SRC (0.76) SRCKDREGFRLCKYES1
SCHEMBL3277003 0.83 SRC (1.00) SRCKDREGFRLCKYES1
SCHEMBL3275753 0.82 SRC (0.69) SRCKDREGFRLCKYES1
SCHEMBL3276447 0.82 SRC (0.69) SRCKDREGFRLCKYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1450808-B8 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-01-04 EP disclosed
EP-1450808-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES Astrazeneca AB (SE) 2004-09-01 EP disclosed
WO-2003045395-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-06-05 WO disclosed